Buspirone (Buspirone hydrochloride)
Also sold as: Busipar, Anxipar, Buspin, Buspar, Buspirol
Pregnancy
Cat B
Lactation
Unknown
Schedule
H
Forms
Tablets 5mg, 10mg +1
Indications
- Generalised anxiety disorder (GAD) — first-line non-benzodiazepine option
- Anxiety with comorbid depression (adjunctive use)
- Augmentation in treatment-resistant depression (off-label)
- Anxiety in patients with alcohol use disorder (non-addictive advantage)
Adult Dosing
Generalised anxiety disorder
5mg
Three times daily (TDS) for 1 week; increase by 5mg/day every 2–3 days as needed. Usual dose 15–30mg/day in divided doses.
CRITICAL: Buspirone requires 2–4 weeks to show full anxiolytic effect — patients must be counselled about delayed onset. Not effective for acute anxiety or panic attacks.
Augmentation for depression (off-label)
5–15mg
Twice to three times daily as adjunct to antidepressant
Pediatric Dosing
Limited data in children. Not approved for paediatric anxiety. Off-label use occasionally considered in paediatric patients with GAD when SSRIs are insufficient — only under specialist supervision.
Renal Dose Adjustment
| CrCl / eGFR | Dose Adjustment |
|---|---|
| Mild-moderate renal impairment | Reduce dose; use with caution |
| Severe renal impairment | Avoid — buspirone is contraindicated in severe renal impairment (significant reduction in clearance) |
Hepatic Adjustment
Contraindicated in severe hepatic impairment. Reduce dose in mild-moderate impairment (extensive first-pass hepatic metabolism via CYP3A4). Start with 5mg BD and titrate slowly.
Pregnancy & Lactation
Pregnancy: Category B
Animal studies show no fetal harm. No controlled human studies. Generally considered safer than benzodiazepines in pregnancy. Use only if clearly needed. Preferred anxiolytic when pharmacotherapy is deemed necessary in pregnancy.
Lactation: Unknown
Unknown if excreted in human breast milk. Animal studies show excretion in milk. Use with caution; consider risk-benefit. Monitor infant for sedation.
Top Drug Interactions
| Interacting Drug | Effect | Severity |
|---|---|---|
| MAO Inhibitors | Potentially fatal hypertensive crisis. Absolutely contraindicated. 14-day washout required. | Major |
| CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, grapefruit juice) | Markedly increase buspirone plasma levels (up to 13-fold with ketoconazole). Reduce buspirone dose to 2.5mg BD if CYP3A4 inhibitor is essential. | Major |
| CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, dexamethasone) | Dramatically reduce buspirone levels (rifampicin reduces AUC by ~83%). Loss of therapeutic effect. Avoid combination; if used, very high doses of buspirone may be needed. | Moderate |
| SSRIs / SNRIs / Serotonergic agents | Buspirone has serotonergic activity (5-HT1A partial agonist) — additive serotonergic effects; monitor for serotonin syndrome with other serotonergic drugs | Moderate |
| Alcohol / CNS depressants | Unlike benzodiazepines, buspirone does NOT significantly potentiate CNS depression of alcohol. However, still not recommended to mix. Caution warranted. | Minor |
DoctorScribe — AI Medical Scribe
Stop looking up Buspirone — just speak the prescription
"Buspirone as per dose, BD for 5 days." DoctorScribe writes the full prescription with brand, strength, frequency, and route — auto-applies pediatric weight-based dosing and renal adjustments. Try the live demo.
Side Effects
Common
- Dizziness (most common)
- Nausea
- Headache
- Nervousness / excitability (at initiation)
- Drowsiness (less than benzodiazepines)
- Fatigue
- Dry mouth
- Blurred vision (less anticholinergic than other anxiolytics)
Serious / Discontinue If
- Serotonin syndrome (with MAOIs or high-dose serotonergic combinations — rare but reported)
- Movement disorders: restlessness (akathisia-like), dyskinesia, Parkinson-like symptoms (rare, usually with high doses)
- Seizures (very rare; may lower threshold)
Contraindications
- Concurrent use with or within 14 days of MAO inhibitors
- Severe renal impairment
- Severe hepatic impairment
- Hypersensitivity to buspirone
Available Indian Brands
| Brand | Manufacturer | Price (approx) |
|---|---|---|
| Busipar 10 | Sun Pharmaceutical Industries | 10 tab ₹42 |
| Anxipar 10 | Cipla Ltd. | 10 tab ₹38 |
| Buspin 10 | Sun Pharmaceutical Industries | 10 tab ₹35 |
| Buspirol 10 | Intas Pharmaceuticals | 10 tab ₹32 |
| Buspar 5 | Bristol-Myers Squibb (BMS) India | 10 tab ₹55 |
Monitoring Required
- Therapeutic response — reassess at 4–6 weeks (delayed onset drug)
- Liver function — baseline recommended given extensive hepatic metabolism
- Renal function — contraindicated in severe renal impairment
- Movement disorders — monitor for dystonia or akathisia at higher doses
- Patient adherence — patients often discontinue prematurely due to delayed onset (counsel explicitly)
Patient Counseling Points
- NOT A BENZODIAZEPINE: Buspirone works completely differently from diazepam or alprazolam. It is NOT addictive and does NOT cause dependence or withdrawal.
- DELAYED ONSET — MOST IMPORTANT: Buspirone takes 2–4 weeks to work for anxiety. Do not judge effectiveness before 4 weeks. Do not stop early because it seems not to be working.
- NOT FOR PANIC ATTACKS: Buspirone is not effective for acute panic attacks or sudden anxiety episodes. It is a preventive medicine taken regularly every day.
- If you were previously on a benzodiazepine: You may experience rebound anxiety when switching — the transition must be managed by your doctor (gradual benzo taper while starting buspirone).
- Avoid grapefruit juice — significantly increases buspirone blood levels.
- Take at the same times every day — consistent administration helps maintain steady blood levels.
- Safe with alcohol (much less interaction than benzodiazepines), but still best to avoid alcohol during anxiety treatment.
- Can be taken long-term without addiction concern — this is a major advantage over benzodiazepines.
Stop Googling drug references mid-consultation
EasyClinic auto-flags Buspirone interactions, renal cutoffs, and pregnancy warnings the moment you write the prescription. Built-in safety net for every Indian doctor.
Clinically reviewed by: Dr. Madhavi Krishnan, MD Psychiatry — Christian Medical College Vellore
Last reviewed: 2026-04-01
References
- Indian National Formulary (INF) 2023 — Buspirone monograph
- CDSCO Prescribing Information — Buspirone hydrochloride
- Goodman & Gilman's Pharmacological Basis of Therapeutics, 13th ed., Chapter 17
- NICE Generalised Anxiety Disorder NG197, 2020 (updated 2022)
- Bandelow B et al. Efficacy of treatments for anxiety disorders — meta-analysis. Int J Neuropsychopharmacol. 2022.
- APA Practice Guidelines for GAD, 2023
- Hale T. Medications and Mothers' Milk, 2023 — Buspirone entry